Navigation Links
Combination therapy shows positive response for children with ADHD
Date:1/9/2012

Washington D.C., January 9, 2012 - While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent. A recent study by Dr. Timothy E. Wilens and colleagues, published in the January 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), is the first randomized placebo-controlled trial designed to assess efficacy and safety of guanfacine extended release (GXR) as an adjunct to psychostimulants in children and adolescents diagnosed with ADHD who had a suboptimal response to a psychostimulant alone.

As reported in the article "A Controlled Trial of Extended-release Guanfacine and Psychostimulants for Attention-deficit/hyperactivity disorder," Wilens and colleagues conducted a nine week multicenter, double-blind, placebo-controlled, dose-optimization study, with participants in 59 study sites who continued their stable dose of psychostimulant given in the morning and were randomized to receive GXR in the morning, GXR in the evening, or placebo.

For both morning and evening administration of GXR, subjects receiving GXR plus a psychostimulant showed significantly greater improvement from baseline to endpoint, as measured by the ADHD-Rating Scale IV total score, compared with subjects receiving placebo plus a psychostimulant. In particular, the inattention subscale rating and the hyperactivity/ impulsivity subscales of the ADHD-RS-IV showed significantly greater improvements from baseline in subjects receiving GXR with a psychostimulant compared with subjects receiving placebo plus psychostimulant. Significant benefits of adjunctive administration were observed whether GXR was administered in the morning or evening. No new safety signals emerged after adjunctive administration of GXR with psychostimulants compared with psychostimulants alone.

Reflecting on their research findings, Wilens and colleagues stated, "The results of this study support the hypothesis that adjunctive administration of the selective alpha2A-adrenoceptoragonist, GXR, to a psychostimulant in subjects with suboptimal response to psychostimulants reduces ADHD symptoms over placebo with a psychostimulant."


'/>"/>

Contact: Mary Billingsley
mbillingsley@jaacap.org
202-966-7300 x105
Elsevier
Source:Eurekalert

Related medicine news :

1. Severe alcoholic hepatitis: An effective combination of 2 treatments
2. Combination epigenetic therapy clinical trial results
3. NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth
4. Combination of available tests helps predict Alzheimers disease risk
5. Combination therapies for drug-resistant cancers
6. Combination therapy beneficial for head and neck skin carcinomas, UNC study shows
7. Phase II study shows new cancer drug combination significantly delays breast cancer progression
8. Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
9. Combination therapy rids common infection from implanted medical devices
10. Metformin and exercise combination less effective for glucose control
11. Combination of existing safety checks could greatly reduce radiotherapy errors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud to ... Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This segment ... to address the limitations of fatigue monitoring technologies within the mining industry. Today ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... taught by healthcare management and evaluation leaders with decades of experience who remain ... in the United States healthcare system, there is a renewed demand for versatile, ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... 23, 2017 , ... Steviva Ingredients, makers of all-natural sweeteners ... National Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. ... handling systems to complement our current rigorous food-safety management systems,” said Yishu Hou, ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... partnership with the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia ... Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Jan. 20, 2017 ResMed (NYSE: RMD ), ... Winter Haven, Florida ) today announced they have agreed ... and 3B will be permitted to sell their existing products in ... one-time settlement payment to 3B to close the Florida ... include an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... Jan. 20, 2017  Faruqi & Faruqi, LLP, a leading ... or the "Company") (NASDAQ: KMPH ) of the ... certain officers and directors and underwriters of the Company,s April ... role of lead plaintiff. The lawsuit has been ... for Johnson County on behalf of ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
Breaking Medicine Technology: